ImmunoGen’s ovarian cancer comeback not as rosy as expected as progression-free survival lags
Back in November, ImmunoGen rallied investors with what looked like a come-from-behind Phase III win. But this morning, the biotech was back to playing defense after disappointing analysts with the details.
ImmunoGen’s second shot at getting mirvetuximab soravtansine across the finish line became a little hazier this weekend. Investors wanted more than 5 months of progression-free survival, but mirvetuximab could only deliver 4.3 months in the SORAYA trial of patients with a certain ovarian cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.